Trial Profile

Crossover, Double-blind, Phase 2 Study of AD128 Versus Placebo in Obstructive Sleep Apnea

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 28 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AD 128 (Primary)
Indications Sleep apnoea syndrome
Focus Proof of concept; Therapeutic Use
Acronyms RebOx

Most Recent Events

17 Sep 2021 Results assessing effects of Oxybutynin/reboxetine combination therapy on OSA pathophysiological (or endotypic) traits published in the Chest
19 May 2021 Primary endpoint has been met. (Change in Apnea-Hypopnea Index (AHI), as per Results presented at the 117th International Conference of the American Thoracic Society
19 May 2021 Results presented at the 117th International Conference of the American Thoracic Society

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com